NDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
OLUMIANT (baricitinib) by Eli Lilly and Company is janus kinase inhibitors [moa]. Approved for janus kinase inhibitor [epc]. First approved in 2018.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLUMIANT (baricitinib) is an oral Janus Kinase (JAK) inhibitor approved by the FDA in May 2018 for treating inflammatory and autoimmune conditions. It works by selectively inhibiting JAK enzymes to suppress pathogenic immune signaling. The drug represents a shift toward targeted small-molecule immunomodulation in place of traditional biologics.
Peak6.4 years to LOE
Peak-stage product with established market presence; brand and specialty teams likely operating at steady-state headcount with focus on market defense and indication expansion.
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Baricitinib Curative Repression of HIV-1
Started Jul 2026
20 enrolled
HIV InfectionHIV
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Started Jun 2026
20 enrolled
Hyper IgE Syndrome From STAT3 MutationJob s SyndromeHIES+2 more
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Started Apr 2026
10 enrolled
Cardiac Sarcoidosis
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Started Feb 2026
300 enrolled
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Started Jan 2026
150 enrolled
Diabetes Mellitus, Type 1
Worked on OLUMIANT at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.